Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
Romaguera JE, Fayad LE, McLaughlin P, Pro B, Rodriguez A, Wang M, Weaver P, Hartig K, Kwak LW, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A. Romaguera JE, et al. Br J Haematol. 2010 Oct;151(1):47-53. doi: 10.1111/j.1365-2141.2010.08315.x. Epub 2010 Aug 5. Br J Haematol. 2010. PMID: 20735402 Free article. Clinical Trial.
Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD.
Mato AR, Svoboda J, Feldman T, Zielonka T, Agress H, Panush D, Miller M, Toth P, Lizotte PM, Nasta S, Goldberg S, Chong E, Schuster S, Pecora AL, Goy A. Mato AR, et al. Cancer. 2012 Jul 15;118(14):3565-70. doi: 10.1002/cncr.26731. Epub 2011 Dec 16. Cancer. 2012. PMID: 22180256 Free article.
Liquid tumors in the elderly.
Mato A, Feldman T, Richter J, Siegel DS, Goy A. Mato A, et al. Clin Geriatr Med. 2012 Feb;28(1):115-52. doi: 10.1016/j.cger.2011.12.002. Clin Geriatr Med. 2012. PMID: 22326039 No abstract available.
Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM. Abramson JS, et al. Ann Oncol. 2014 Nov;25(11):2211-2217. doi: 10.1093/annonc/mdu443. Epub 2014 Sep 5. Ann Oncol. 2014. PMID: 25193992 Free PMC article.
Targeting indolent non-Hodgkin lymphoma.
Leslie LA, Skarbnik AP, Bejot C, Stives S, Feldman TA, Goy AH. Leslie LA, et al. Among authors: feldman ta. Expert Rev Hematol. 2017 Apr;10(4):299-313. doi: 10.1080/17474086.2017.1303374. Epub 2017 Mar 15. Expert Rev Hematol. 2017. PMID: 28277849 Review.
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach.
Roeker LE, Feldman TA, Soumerai JD, Falco V, Panton G, Dorsey C, Zelenetz AD, Falchi L, Park JH, Straus DJ, Pena Velasquez C, Lebowitz S, Fox Y, Battiato K, Laudati C, Thompson MC, McCarthy E, Kdiry S, Martignetti R, Turpuseema T, Purdom M, Paskalis D, Miskin HP, Sportelli P, Leslie LA, Mato AR. Roeker LE, et al. Among authors: feldman ta. Clin Cancer Res. 2022 Sep 15;28(18):3958-3964. doi: 10.1158/1078-0432.CCR-22-0964. Clin Cancer Res. 2022. PMID: 35852793 Free PMC article. Clinical Trial.
34 results